Nephrocare Health Services reported a consolidated revenue from operations of ₹2.8 billion for Q1FY27, up from ₹2.3 billion in the same period last year, reflecting strong year-on-year growth. Consolidated net profit rose to ₹320 million compared to ₹237 million in Q1FY26. The Hyderabad-based dialysis provider also saw its adjusted EBITDA surge 30.7% to ₹65.1 crore, driven by steady volume growth and improved operating leverage. Treatments rose 13.3% to 10.31 lakh, while revenue per treatment improved 9.2% to ₹2,733. The strong performance underscores the company's ability to scale profitably across domestic and international markets.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 11, 2026. The results were reviewed by M/s. B S R and Co, Chartered Accountants (FRN - 128510W), the statutory auditors of the company, under Regulation 33 of the SEBI Listing Regulations. The company also disclosed its investor presentation pursuant to Regulation 30 of the SEBI Listing Regulations.

Financial Performance

Consolidated revenue reached ₹2.8 billion in Q1FY27, compared to ₹2.3 billion in Q1FY26. Reported EBITDA came in at ₹603 million versus ₹476 million in the prior year period, with the reported EBITDA margin expanding to 21.41% from 20.88% YoY. Adjusted EBITDA stood at ₹65.1 crore, representing a 30.7% YoY increase, with the adjusted EBITDA margin at 23.1%—up 120 basis points YoY and improving 220 basis points sequentially over Q4FY26 (20.9%). Adjusted profit after tax (PAT), which adds back Saudi expenses and ESOP expenses, grew 41.7% YoY to ₹36.8 crore. Standalone revenue from operations was ₹1,704 million, up from ₹1,488 million in Q1FY25. Basic earnings per share (EPS) increased to ₹3.19 on a consolidated basis.

The table below summarises the key reported and adjusted financial metrics for the quarter:

Operational Growth and International Expansion

The group executed seven acquisitions in the Philippines during Q1FY27, bringing the total clinic count there to 51. In Uzbekistan, the network expanded its footprint in Kungrad and Beruniy, now serving 1,400+ guests across six clinics. In Saudi Arabia, home dialysis treatments commenced, and a medical operator license was obtained. A 51:49 joint venture with Arabian International Healthcare Holding Company (Tibbiyah) was established to scale operations in the Kingdom.

In India, NephroPlus serves over 33,000 guests in 487 clinics across 307 cities. The company added 6 captive clinics, 18 PPP clinics, and 8 standalone clinics in Q1FY27. Approximately 52% of clinics operate under a revenue-sharing model, limiting upfront capital investment. The company launched the NephroPlus International Dialysis Academy (NIDA) to build a pipeline of renal nurses for global staffing needs.

What the Numbers Show

The expansion of reported EBITDA margin to 21.41% and adjusted EBITDA margin to 23.1% demonstrates strong operating leverage as treatment volumes grew faster than costs. The sequential improvement of 220 basis points from Q4FY26 in adjusted EBITDA margin indicates accelerating efficiency. Management highlighted that each line item—revenue, EBITDA, and PAT—outpaced the previous one, signaling robust platform strength converting scale into higher profitability.

Nephrocare Health Services has approved trading plans for two senior executives to sell their equity holdings, providing transparency on potential supply pressure in the coming months. The company intimated the Bombay Stock Exchange and the National Stock Exchange on August 5, 2026, regarding the pre-approved plans submitted by Group Chief Executive Officer Rohit Singh and CEO India and Nepal Business Sukaran Singh Saluja. These disclosures are mandatory under Regulation 5(5) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, ensuring that designated persons trade within predefined parameters to prevent insider trading concerns.

The trading plans were approved on August 5, 2026, following submission by the respective executives. The plans are irrevocable once approved, meaning the executives must execute the trades if market conditions permit, though they retain the right not to trade if unpublished price-sensitive information remains undisclosed. The price limits for these transactions were derived from the closing price on August 4, 2026, which stood at ₹713.15 on the National Stock Exchange of India Ltd. The minimum execution price is set at ₹700.00 per equity share, representing a buffer of up to 20% below the reference closing price.

Trading Plan Details

Both executives have scheduled their sales for the same five-day window in December 2026. The specific terms of the approved plans are outlined below:

Rohit Singh’s plan involves the sale of 30,000 equity shares, while Sukaran Singh Saluja intends to sell 60,000 equity shares. The total number of shares slated for sale under these plans is 90,000. The trading window is fixed between Monday, December 7, 2026, and Friday, December 11, 2026.

Regulatory Compliance and Conditions

The executives confirmed adherence to the cool-off period of 120 calendar days as prescribed under Regulation 5(2)(i) of the SEBI PIT Regulations. They also undertook not to trade for market abuse purposes. A critical condition of these plans is that execution will only occur if the stock price remains within the specified limit range; if the price falls below ₹700.00 or rises significantly above the upper bound implied by the derivation method, the trades may not be executed as planned. Furthermore, neither executive will implement the plan if any unpublished price-sensitive information held at the time of formulation has not become generally available by the commencement of the trading period.

What This Means for Investors

The disclosure of these trading plans allows investors to anticipate potential selling pressure from key insiders during the specified December window. While the sales are structured to comply with regulatory safeguards against insider trading, the volume of 90,000 shares represents a notable liquidity event. Investors should monitor the stock’s price action relative to the ₹700 floor during the December 7–11 period, as any deviation could signal changes in market sentiment or execution delays.